Skip to main content
. 2020 Aug 13;106(1):313–315. doi: 10.3324/haematol.2020.260448

Figure 2.

Figure 2.

Allele frequencies in six JAK2/CALR and seven JAK2/MPL comutated patients detected among a series of 2,664 consecutive diagnostic samples assessed for myeloproliferative neoplasms. The median allele frequency for JAK2 is significantly lower than for either comutated CALR (JAK2 vs. CALR, median 0.32% [range: 0.02-2.83%] versus 24.90% [range: 10.30-43.98%]) or comutated MPL (JAK2 vs. MPL, median 1.96% [range 0.50%- 20.12%] versus 19.88% [range: 8.51-37.61%]).